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Sarcopenia, the age-related loss of skeletal muscle mass and function, is becoming more
prevalent as the lifespan continues to increase in most populations. As sarcopenia is
highly disabling, being associated with increased risk of dependence, falls, fractures,
weakness, disability, and death, development of approaches to its prevention and treat-
ment are required. Androgens are the main physiologic anabolic steroid hormones and
normal testosterone levels are necessary for a range of developmental and biological
processes, including maintenance of muscle mass. Testosterone concentrations decline
as age increase, suggesting that low plasma testosterone levels can cause or accelerate
muscle- and age-related diseases, as sarcopenia. Currently, there is increasing interest on
the anabolic properties of testosterone for therapeutic use in muscle diseases including sar-
copenia. However, the pathophysiological mechanisms underlying this muscle syndrome
and its relationship with plasma level of androgens are not completely understood. This
review discusses the recent findings regarding sarcopenia, the intrinsic, and extrinsic mech-
anisms involved in the onset and progression of this disease and the treatment approaches
that have been developed based on testosterone deficiency and their implications.
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INTRODUCTION
In healthy young adults, the skeletal muscle mass comprises
approximately 60% of total body mass. From age 40, the per-
centage begins to decline, reaching 40% at 70 years-old (1). This
age-related decline in skeletal muscle mass and strength genera-
tion, the primary function of skeletal muscle mass, is known as
sarcopenia (2, 3). This newly identified syndrome impacts both
quality and quantity of life for both men and women, often lead-
ing to physical disabilities, gait abnormalities, and falls that cause
loss of functional independence (4). Although sarcopenia is affect-
ing more and more population worldwide, its pathophysiology
remains unclear. Such lack of clarity can be attributed to diffi-
culty in isolating the individual events responsible for alterations
in skeletal muscle, most of which occur simultaneously, among
the multiple age-associated changes and co-morbidities associated
with advanced age. Indeed, most of the intrinsic as well as extrinsic
(systemic) muscle changes that occur with age are believed to be
involved in the development of sarcopenia (5, 6).
The difficulty in defining sarcopenia has created challenges
in determining the best treatment for patients with this disease.
Among the many different therapeutic approaches, including exer-
cise, hormone, nutritional therapy, and/or a combination thereof,
no one approach has emerged as superior in animal or human
studies, and the great variability in the clinical outcomes of patients
treated with these approaches has prevented identification of the
most effective therapy (7, 8). One approach that has drawn recent
attention is supplementation with androgens, hormones with ana-
bolic properties whose levels naturally decline with age (9–12).
Clinical studies of androgen supplementation in age-related dis-
eases and muscle wasting are a focus of emerging interest (11).
Skeletal muscle is a target tissue for anabolic steroids. Testos-
terone elicits significant muscular effects and abnormalities of
plasma concentrations can cause muscle disease (13). High lev-
els are associated with muscle hypertrophy, whereas low levels are
epidemiologically associated with metabolic syndrome and dia-
betes, which negatively impact muscle functions. However, most
evidence linked testosterone and skeletal muscle effects are obser-
vational. Studies targeted at establishing such effects at cellular
level and their correlations with in vivo models, will broaden our
understanding of the roles played by androgens on skeletal muscle
function in elderly.
PREVALENCE OF SARCOPENIA
The term sarcopenia was first proposed in 1989 by Irwin Rosen-
berg to describe a multifactorial syndrome that occurs with age
and results in loss of skeletal muscle mass and function (3,
4). Prior to publication of the Report of the European Work-
ing Group on Sarcopenia in Older People (EWGSOP) in 2010,
a variety of definitions of sarcopenia and inclusion criteria for
patients with sarcopenia were used in epidemiological studies. In
this report, the EWGSOP defined sarcopenia as a syndrome char-
acterized by progressive and generalized loss of skeletal muscle
mass and strength associated with physical disability, poor qual-
ity of life, and risk of death, and they also recommended criteria
for diagnosis (14). Importantly, the recent development of these
clear definitions and guidelines to diagnose and treat sarcopenia
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has significantly improved understanding of this relatively newly
identified condition.
Although epidemiological research into sarcopenia has iden-
tified factors potentially associated with its prevalence, such as
testosterone levels (15), most research has been cross-sectional
rather than longitudinal, the approach that is necessary to increase
our understanding. The prevalence of sarcopenia is partially
dependent on the population studied, the measurement technique
employed, and the operational definition used. Some authors
report that sarcopenia affects both Hispanic and non-Hispanic
white men and women, with prevalence ranging from 13.5 to
24% in individuals under 70 years, reaching 60% in individuals
above 80 years. Also sarcopenia was significantly associated with
several co-morbidities and lifestyle factors, including obesity, low
income, current smoking, and lung disease (4). Regarding gen-
der differences in muscle distribution, it has been observed that
woman had up to 40% less muscle in the upper body but no more
than 33% less mass in the lower body compared to man (16). At
a transcriptional level, a marked sexual dimorphism was observed
on the biceps brachii muscle. According to the authors, it appears
that mainly age-induced changes at the transcriptional level in
women, were responsible for increased expression levels of signal-
ing pathways dealing with muscle dysfunction, inflammation, and
mitochondrial dysfunction, thus leading to an alteration in “mus-
cle quality” (17). On the contrary, regarding total muscle mass,
age-related loss in total body muscle mass was greater in the male
than female subjects, independent of change in stature, and can
be clearly observed after approximately age 45. Also these results
indicate that age-related loss of skeletal muscle mass is greater in
the lower than upper body in both men and women (16). Clini-
cal studies reveal that sarcopenia is a main cause of higher frailty,
impairment, and loss of independence in elderly women than men
(18). In addition, other cause contributing to sarcopenia is related
to physical activity, which declines with age. Other indirect factors
such as inflammation and oxidative stress also have been suggested
to contribute to sarcopenia development. One of these factors that
represent differences in men and women is the etiology of adipose
tissue, which is a potent source of pro-inflammatory cytokines,
suggesting that sex differences in total and regional adiposity can
impact sarcopenia development.
Observation of a relationship between testosterone level and
skeletal muscle anabolism has led to research evaluating age-
related declines in testosterone levels. In a cross-sectional study,
Feldman et al. (19) determined that total testosterone level
declined approximately 0.8% per year and that both free and
albumin-bound testosterone level declined approximately 2% per
year after age 40, whereas sex hormone-binding globulin (SHBG)
increased by 1.6% per year. In a subsequent longitudinal analy-
sis, they determined that total testosterone declined by 1.6% per
year and bioavailable testosterone declined by 2–3% per year. In
a third study, they found that both testosterone level and the
free testosterone index decreased progressively from the third
to the ninth decades of life, specifically that total testosterone
level decreased an average 0.110 nmol/L per year and the free
testosterone index an average of 0.0049 nmol testosterone per
nanomole SHBG per year, regardless of whether these variables
were examined cross-sectional or longitudinally (19).
CELLULAR AND MOLECULAR MECHANISMS UNDERLYING
SARCOPENIA
Although the pathophysiology of sarcopenia remains under inves-
tigation, two main groups of factors have been identified as
responsible for its development: (1) intrinsic factors at the cellular
level, such as mitochondrial malfunction and oxidative stress; (2)
systemic factors, such as production of inflammatory cytokines,
changes in hormone levels, and overall decrease in physical activ-
ity level. Loss of muscle mass and functionality related to sar-
copenia cannot be completely explained by atrophy of muscle
fibers. As such, the involvement of several atrophy-independent
mechanisms in these conditions has been postulated, including
decrease in myosin force and/or actin–myosin cross-bridge stabil-
ity and defective excitation–contraction coupling (20, 21). From a
descriptive/histological point of view, sarcopenia induces a change
in the proportion of skeletal muscle fibers, inducing a shift from
type II (fast) to type I (slow) fibers as well as preferential loss
of type II fibers (22). This fiber-type change impacts not only
the strength but also the power of particular muscles, and may be
upstream of the signs of mobility limitation observed in sarcopenic
patients (23).
EXTRINSIC FACTORS: AGING AS A MULTISYSTEM PROCESS
The aging process affects the physiology of many systems that
work together to achieve the main function of the musculoskeletal
system; namely, motion. Thus, age-related changes in these sys-
tems, especially those that affect neurological, inflammatory, and
hormonal behavior may be directly related to sarcopenia.
Androgen levels as extrinsic factor for sarcopenia
In addition to a natural decrease in testosterone levels due to age,
abnormal levels of plasma testosterone are observed in men suf-
fering from late-onset hypogonadism, loss of testicular mass, and
endocrine diseases involving low androgen production, acceler-
ated testosterone metabolism or malfunctioning androgen recep-
tor (24, 25). Currently it is recognized that low plasma testosterone
is associated with metabolic syndrome, diabetes, and cardiovascu-
lar diseases (26); however, the impact of low plasma testosterone
levels on skeletal muscle in elderly is still controversial. Because
testosterone is the main physiological anabolic hormone, a decline
in its plasma concentrations by age must be considered one of
the causes for loss of muscle mass and an extrinsic factor for
sarcopenia.
Figure 1 shows the relationship between androgen levels and
the development of sarcopenia. Androgen supplementation has
been observed to exert anabolic actions that enhance muscle
strength and increase muscle size clinically (27–31). Although
the biological mechanisms underlying androgen action in skeletal
muscle remain poorly understood, muscle mass has been observed
to be regulated by the normal balance between synthesis and degra-
dation of muscle proteins, a mechanism that is regulated by various
systemic hormones. Levels of circulating testosterone, estrogens,
IGF-1, vitamin D, and thyroid hormones have been observed to
decrease with age (5, 32). While the association between testos-
terone and increase in skeletal muscle mass has been recognized for
many years, it was not formally described until 1996, when Bhasin
et al. demonstrated the anabolic effects of testosterone in a study
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FIGURE 1 | (A) Relationship between levels of androgens and anabolism of
skeletal muscle and their effects on muscle mass and strength. (B) Cellular
effects of testosterone on skeletal muscle.
of testosterone-treated vs. placebo-treated young men (9). While
this study and subsequent studies provided evidence for anabolic
properties of testosterone at all ages, none directly identified the
mechanism underlying the relationship between testosterone lev-
els and muscle mass with aging. In a cross-sectional study of
1,445 men, Krasnoff et al. (33) found no significant associations
between either total testosterone or SHBG level and mobility, sub-
jective health, or any physical performance measure, but did find
an inverse association between free testosterone level and subjec-
tive health and a direct association between free testosterone level
and usual walking speed and short physical performance battery
score. In a subsequent longitudinal analysis, the authors found
that free testosterone levels were also significantly associated with
progression of mobility limitation (33). Specifically, they found
that men with low free testosterone levels were 57% more likely
to develop mobility limitation and 68% to experience increase in
mobility limitation compared to men with normal testosterone
levels. In support of this finding, Malmström et al. found that
when the value is adjusted for height, bioavailable testosterone is
responsible for 2.6% of the variance in appendicular skeletal mus-
cle mass (ASM), which represents 75% of the total skeletal muscle
mass (34).
Clinically, androgen supplementation has been observed to
exert anabolic actions that enhance muscle strength and increase
muscle size. While elevated plasma androgen concentrations are
known to induce skeletal muscle hypertrophy (35), the cellu-
lar mechanisms by which testosterone increases skeletal muscle
mass remain under investigation. Research to date indicates that
testosterone stimulates protein synthesis by both a short-term
mechanism-rapid activation of pre-existing components of the
translational apparatus- and a long-term mechanism-increase
in cell or tissue capacity at the protein synthesis level lead-
ing to increase in ribosome quantity (36). At the cellular level,
Sinha-Hikim et al. observed that testosterone induces an increase
in cross-sectional area (CSA) in type I and II muscle fibers and
in myonuclear quantity, indicating that testosterone exerts more
of a hypertrophic than a hyperplasic effect on skeletal muscle
(30). At mechanistic level, have been observed that testosterone
exerts a rapid non-genomic effect on skeletal muscle cells simi-
lar to that exerted by other steroid hormones such as estrogen,
progesterone, vitamin D3, and aldosterone in different cellu-
lar types (37). In rat myotubes, a type of “immature” muscle
fiber, our group recently observed rapid phosphorylation of Akt
via phosphatidylinositol-3 kinase (PI3K) and subsequent phos-
phorylation of mammalian target of rapamycin (mTOR), which
lies upstream of the critical translation regulator 40S ribosomal
protein S6 kinase 1 (S6K1), to increase protein synthesis (38).
mTOR represents a key controller of anabolic processes, particu-
larly translation initiation and elongation that produce muscular
protein. By activating mTOR, testosterone may induce phospho-
rylation of eIF4E-binding protein 1 (4E-BP1) and its release from
eIF4E, a cap-binding factor that can be sequestered in inac-
tive complexes by 4E-BP1, allowing for generation of initiation
factor complexes (39). Moreover, testosterone-induced activa-
tion of the PI3K/Akt/mTOR/S6K1 axis combined with “classic”
androgen-mediated action in rat myotubes has been observed
to lead to hypertrophy, as evidenced by an increase in the CSA
of testosterone-treated myotubes and levels of α-actin contractile
protein (38). Other pathways have been hypothesized to underlie
testosterone-induced hypertrophy. In a study of the cellular line
L6, Wu et al. observed that testosterone treatment induced acti-
vation of mTOR, but more slowly (within 2 h) than had previous
studies and in a manner not mediated by PI3K/Akt but rather
MAPK (40). After confirming the anabolic potential of testos-
terone both in vivo and in vitro,White et al. described the activation
of mTOR as dependent on the concentration of testosterone (41).
For us, this point is critical to make comparisons between different
studies and the effectiveness of therapy testosterone replacement,
mainly because differences between the physiological effects of
testosterone and changes in its plasma concentration, either low
or high levels, may trigger different intracellular mechanisms for
testosterone actions on skeletal muscle.
In summary, recent studies have found that testosterone acti-
vates multiple signal transduction pathways to induce hypertro-
phy, including the MEK-ERK and PI3K/Akt pathways; that the
energy sensors mTOR and AMP-activated protein kinase (AMPK)
control cell growth and metabolism in testosterone-induced skele-
tal and cardiac hypertrophy (38, 42); and that alterations in mTOR
pathway in aging muscle decrease the kinase activity of mTOR and
its downstream targets, decreasing anabolic activity in response
to external stimuli, such as growth factor production, nutrient
ingestion, and physical activity (43). In the emergent research into
the early signals that mediate the activation/deactivation of these
essential metabolic pathways, mTOR has been identified as a key
element in the regulation of translation and cell growth; namely, as
a“master regulator” in a network that detects the energy and nutri-
tional status and genotoxic stress level of cells (44). Identification
of the central role of testosterone in metabolism and its effects on
mTOR pathway have led it to become a subject of intense interest
in aging research and pharmacological treatment for sarcopenia.
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Inflammatory cytokine production
Loss of skeletal muscle in sarcopenia may result from reduc-
tion in muscle protein synthesis and/or increased muscle protein
breakdown, both of which are associated with inflammation. In
this sense, other hypotheses regarding sarcopenia pathophysiology
focus on the role of chronic low-grade inflammation, specifically
that related to circulating levels of IL-6 and tumor necrosis factor-
α (TNF-α). In a study of the relationship between muscle mass
and strength in healthy individuals aged 70–79 years, Visser et al.
found IL-6 levels of >1.80 pg/ml and TNF-α levels >3.20 pg/ml
to be associated with smaller muscle area, lower appendicular
muscle mass, and less strength, even after correcting for presence
of inflammatory-associated diseases, height, and smoking (45).
One mechanism hypothesized to underlie muscular atrophy in
response to elevated TNF-α level is an increase in the ubiquitin-
conjugating activity of the E2 protein UbcH2/E220K. In a study
using cultured myotubes, Li et al. detected NF-κB mediated up-
regulation of UbcH2 at the mRNA level after 90 min of TNF-α
stimulation and at the protein level after 4 h of stimulation, as
well as an increase in ubiquitin-conjugating activity after 4–6 h
of stimulation to a level that remained elevated for at least 24 h
(46). According to the authors, these findings could explain the
mechanism whereby TNF-α may induce the loss of skeletal mus-
cle proteins. In line with these findings, in a 5-year follow up study
of older healthy individuals Schaap et al. observed a relationship
between inflammatory marker (IL-6, TNF-α, and C-reactive pro-
tein) levels and a decline in muscle mass and strength, as well
as consistent inverse association between levels of TNF-α and its
soluble receptors and thigh muscle area and grip strength (47).
INTRINSIC FACTORS: CHANGES AT THE SKELETAL MUSCLE LEVEL
Intrinsic factors leading to alterations in skeletal muscle involve
various intracellular signaling pathways, which in turn may acti-
vate intracellular modulators in a manner that has long-term
cellular effects. The following sections describe several signaling
pathways that may be involved in loss of strength due to atrophy
of skeletal muscle fibers, a criterion for diagnosis of sarcopenia.
Mitochondrial malfunction and oxidative stress
Among the mechanisms hypothesized to underlie atrophic
changes in sarcopenic muscles, mechanisms at the mitochondr-
ial level have earned strong research support. In a cross-sectional
study comparing active and sedentary elderly adults Safdar et al.
(48) found that a sedentary lifestyle was associated with increased
basal levels of markers of chronic inflammation (interleukin-6 and
C-reactive protein levels), reduced level of markers of mitochon-
drial oxidative capacity (COX activity and levels of citrate synthase
and PGC1-α levels), and deregulation of cellular redox status as
superoxide dismutase (SOD) activity. All these changes, which are
thought to render skeletal muscle fiber more prone to reactive oxy-
gen species (ROS)-mediated toxicity and, consequently, to skeletal
muscle fiber death, led the authors to suggest that mitochondria
alterations and increased oxidative status in skeletal muscle are
involved in sarcopenia development (48).
Oxidative damage and free radical production have also been
associated with a decline in mitochondrial DNA content, pro-
tein synthesis, and activity, as well as in oxidative capacity and
ATP production (49). In a comparison of aged (20 months-old)
Sod1−/− mice, a transgenic mouse model lacking the antioxi-
dant enzyme CuZnSOD, and wild-type mice, Jang et al. observed
greater ROS release (O2− and H2O2) and oxidative damage and
decreased mitochondrial bioenergetic functioning and ATP pro-
duction in the Sod1−/− mice (50). The authors hypothesized
that the consequences of the mitochondrial dysfunction that they
observed in the Sod1−/− mice, which included elevated apoptotic
potential; decrease in myonuclear number per millimeter of fiber
length; and alterations in neuromuscular junction histology and
contractility, also occur in the skeletal muscle of aging humans,
and thus that mitochondrial dysfunction is an important factor in
the pathophysiology of sarcopenia.
Recent in vivo and in vitro studies have highlighted the role of
testosterone in preventing or reversing age-related skeletal muscle
loss. In a recent animal study, a regimen of testosterone admin-
istration and simultaneous low-intensity physical training was
found to improve skeletal muscle mitochondrial biogenesis and
mitochondrial quality control in elderly male mice, suggesting the
importance of maintaining proper testosterone levels for muscle
metabolism (51). In various cellular models, mainly of prostate
cancer cells, low levels of testosterone were found to be associated
with oxidative stress induced by decreased antioxidant levels via
decreased expression of antioxidant enzymes such as SOD, GSH-
Px, and catalase (52). Whereas, testosterone deficiency has been
observed to induce oxidative stress in cardiomyocytes, testosterone
replacement therapy (TRT) has been found capable of suppressing
oxidative stress mediated via the androgen receptor-independent
pathway (52).
Skeletal muscle performance has been related to redox status.
In soleus muscle of sedentary volunteers, Delgado et al. observed
that administration of stanozolol, an anabolic steroid derivate,
increased SOD, and glutathione reductase activities, but induced
no change in other enzyme activities as catalase and glutathione
peroxidase (53). A recent study shows that administration of dihy-
drotestosterone (DHT) to SOD1-G93A-mutated mice ameliorated
muscle atrophy and increased body weight (54). As mutations in
the human SOD1 gene are responsible for the development of
amyotrophic lateral sclerosis (ALS), a late-onset neurodegener-
ative disease characterized by progressive loss of motoneurons,
skeletal muscle weakness, atrophy, and paralysis, the authors sug-
gested that androgen therapy may improve the quality of life
for ALS patients. However, further study of antioxidant regula-
tion by androgens in elderly humans with loss of skeletal muscle
is required before extrapolation of these findings to sarcopenic
patients.
Skeletal muscle apoptosis
Apoptosis, the process of programed cellular self-destruction with-
out inflammation or damage to surrounding tissue, is highly
related to the atrophic process that leads to sarcopenia (55, 56).
Despite observation that this cellular response is driven by spe-
cific signaling pathways and ultimately executed through caspase-
dependent and caspase-independent mechanisms (22), few studies
have attempted to confirm the existence of these mechanisms in
humans (57). Among the few that have, a cross-sectional study
that compared apoptosis levels in the skeletal muscles of elderly
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and young adults observed a higher number of terminal deoxynu-
cleotidyl transferase dUTP nick end labeling (TUNEL)-positive
cells and decreased muscle strength in elderly but no significant
differences in caspase-dependent pathway-related (caspase-3/7)
activity or muscle fiber CSA between the elderly and young (56). In
a study of the relationship between apoptotic activation in skeletal
muscle and indices of muscle function and mass in the elderly
Marzetti et al. found a correlation between biologic apoptosis
markers and muscle mass and function indices in community-
dwelling elderly men and women (58). Specifically, they found
that caspase-dependent apoptotic signaling (caspase-8, cleaved
caspase-3, cytosolic cytochrome c, and mitochondrial Bak activity)
was correlated with percentage of muscle volume, whereas cleaved
caspase-3, Bax, and Bak activity was correlated with gait speed.
Although they found no significant differences regarding these
apoptotic markers in subjects classified as either high function-
ing or low functioning according to whether their percentage of
muscle volume was below or above the median value of the study
sample, they observed higher levels of activated caspase-8 and
cytosolic cytochrome c in the low-functioning subjects (57). These
findings, in addition to evidence obtained from animal research,
support the role of apoptosis as an important mechanism in the
pathophysiology of sarcopenia.
Research has also indicated that testosterone has an anti-
apoptotic effect in C2C12 muscle cells. Pronsato et al. found
that treatment with testosterone at physiological concentrations
inhibited apoptosis that had been induced by treatment with a
high concentration of H2O2 (1 mM) (59). It also induced inac-
tivation of BAD, inhibition of PARP cleavage, decrease in BAX
levels, and exertion of a protective effect at the mitochondrial
membrane potential level. In this line of evidence, testosterone
administration prevented sarcopenia in a mouse model, which
allow to hypothesize that testosterone treatment improves the
regenerative potential of satellite cells and suppresses skeletal mus-
cle cell apoptosis, the latter primarily by inhibiting activation of
the JNK pathway and activating Akt (60). Further research has
confirmed that testosterone supplementation exerts both benefi-
cial and pathological effects on apoptotic process. Depletion of
androgen below normal plasma levels has been found to increase
kainate-induced neuronal loss (61) and induce apoptosis in the
bladder wall of senile male rats (62), while elevated testosterone
has been observed to induce apoptosis in a human neuroblastoma
cell line (63). These findings indicate that the beneficial effects of
androgen are obtained when androgen levels are within a specific
(nanomolar) physiological range, the regulation of which is cru-
cial for normal muscular functioning and a deviation from which
in either direction could be deleterious to muscle health.
Muscle atrophy and Ca2+ signaling
The cellular processes underlying muscle atrophy result in both
qualitative and quantitative alterations in muscle fiber cells and
associated structures. Muscle atrophy leaves particular“signatures”
in the profile of sarcopenic muscle proteins that can be observed,
and muscle proteins are contained in different cellular compart-
ments that can be analyzed. Since contractile proteins are critical
for skeletal muscle function, analyzing changes in these proteins
can assist in understanding the pathophysiology of sarcopenia.
In a study of the synthesis of myosin heavy chain (MHC) pro-
tein over the lifespan and its correlation with muscle strength
and hormone levels, Balagopal et al. (64) found that the rate
of MHC synthesis begins decreasing at age 50 before plateau-
ing at age 75, and observed a correlation between a decrease in
the rate of MHC synthesis and muscle mass, strength measures
and, interestingly, levels of anabolic hormones, including insulin-
like growth factor I (IGF-I) and dehydroepiandrosterone sulfate
(DHEAS) levels in both men and women and free testosterone
level in men. As myosin represents about 25–30% of muscle pro-
tein, a decrease in its synthesis rate would be expected to impact
muscle mass and strength (64). Other protein-specific changes
in senescent skeletal muscle related to decreased muscle function
involve α-actin, Ca-ATPase transporter, ryanodine receptor, and
muscle-specific inositol phosphatase (MIP), a recently described
protein related to Ca2+ homeostasis in skeletal muscle. In a recent
study, Staunton et al. observed a lower level of thin filament α-
actin protein in vastus lateralis muscle biopsy samples taken from
aged subjects compared to those taken from middle-aged sub-
jects (65). Utilizing mass spectrometry-based proteomic analysis,
the authors were able to describe a “signature” of aged vastus lat-
eralis skeletal muscle and detect changes in proteins involved in
excitation–contraction coupling, metabolism, ion handling, and
the cellular stress response. These findings led the authors to sug-
gest that human muscle tissue undergoes a fiber-type shift from
fast to slow contracting muscle tissue with age, an event that has
been previously postulated and demonstrated in other sarcopenic
models (65).
Concerning intracellular Ca2+ handling proteins in skeletal
muscle, Ferrington et al. (66) described a decrease in the rel-
ative protein turnover of the sarcoplasmic reticulum proteins
Ca-ATPase and the ryanodine receptor in aged rats. The authors
hypothesized that alterations in the turnover rate of certain key
Ca2+ handling proteins could account for the functional dis-
turbances observed in skeletal muscle. Our research group has
demonstrated that androgens are able to modulate intracellular
Ca2+ homeostasis within seconds to minutes in different cell sys-
tems using a variety of mechanisms that vary considerably and
depend on the cell type (67–69). In skeletal muscle, we observed
that testosterone stimulation induces rapid (<1 min) oscillation
in intracellular Ca2+ signals, which begin as Ca2+ transients initi-
ated in the cytosol before being propagated as waves of Ca2+ in the
cytoplasm and nucleus (68, 70, 71). This complex process of Ca2+
signaling, which depends on the interplay between IP3-sensitive
stores and extracellular Ca2+ influx, is unaffected by the androgen-
receptor antagonist cyproterone acetate, and apparently mediated
by a pertussis toxin-sensitive G protein-coupled membrane recep-
tor activated by testosterone 3-(O-carboxymethyl)oxime (T-BSA).
Moreover, it has been suggested that a similar manner of con-
formational coupling between IP3 receptors and store-operated
calcium entry (SOCE) is activated in skeletal myotubes during
testosterone-induced Ca2+ oscillations (70). In this sense, age-
related testosterone decrease certainly will affect skeletal muscle
Ca2+ homeostasis.
As described by Shen (72) (MIP/MTMR14), a recently
described protein, is responsible for sarcopenia pathophysiology
by controlling intracellular phosphatidylinositol phosphate (PIP)
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levels via influencing SOCE and Ca2+ storage and release from the
sarcoplasmic reticulum (72). Its importance is evidenced by obser-
vation of significant age-related decreases in levels of MIP mRNA,
protein content, and activity in wild-type mice. Characteristic fea-
tures of sarcopenia (diminished muscle mass, force, and power
generation) also appear much earlier in MIP knock-out (MIPKO)
mice than in their wild-type counterparts. Altered Ca2+ home-
ostasis has also been observed in both mature MIPKO and old
wild-type mice (21). Moreover, muscle aging has been associated
with compromised Ca2+ spark signaling and segregated intracel-
lular Ca2+ release in sarcopenia (73). According to Romero-Suarez
et al. (21), these findings all provide evidence of the important role
of MIP in the physiology and pathology of muscle fiber.
Age-related depletion of muscle stem cells
The sarcopenic process is more pronounced in patients showing
significant loss of muscle stem cells, particularly satellite cells. Sev-
eral reports indicate that it is possible to isolate stem cells from
adult skeletal muscle,but is important to distinguish between satel-
lite cells and muscle-derived stem cells (MDSC). Embryonic stem
cells and induced pluripotent stem cells are another cell source
that can differentiate into muscle cells, but further work is needed
to produce sufficient numbers of cells to generate contractile
myofibers for therapeutic use (74, 75).
The satellite cells are mononucleated cells that lie under or
embedded in the basal lamina of the myofiber, which demonstrate
close relationship with the mature myofiber (75). The satellite
cells are myogenic precursors capable of regenerating skeletal mus-
cle and demonstrate self-renewal properties. During development
and regeneration, quiescent satellite cells are activated and start
proliferating, at this point they are called myogenic precursor
cells or myoblasts (76). Once muscle satellite cells are activated
to become myoblasts, they enter the proliferative stage and dif-
ferentiate into myotubes by expression of MyoD, whereas, the
secondary myogenic regulatory factors (MRF) as myogenin and
MRF4 regulate terminal differentiations. Myofibers derived from
satellite cells show characteristic skeletal muscle markers such as
sarcomeric striations, MHC, MyoD, and desmin expression (77).
In the elderly, the number of satellite cells and their capacity
of cellular regeneration decrease (78). In humans and mice, these
quiescent cells are plentiful at birth but their number declines
with age until 1–5% in adults (74). Different modulators regulate
satellite cell functions in adults. Among them Alway et al. suggest
that satellite cell function is affected by oxidative stress, which is
elevated in aged muscles (79). During the differentiation of satel-
lite cells to muscle a normal mitochondrial oxidative metabolism,
with low production of ROS, is required to sustain skeletal mus-
cle specification and function. However, aging is associated with
excessive production of ROS by increase in mitochondrial dam-
age contributing to impaired satellite cell function (79). Also, the
decrease in satellite cells by age, has been attributed to the change
in percentage of type I vs. type II muscle fibers, because satellite
cells reside surrounding type II muscle fibers (46, 78).
Characterization of this satellite cells-derived skeletal muscle
is determined at molecular, electrophysiological, and functional
levels. At the molecular level, they show muscle-specific mark-
ers including transcription factors such as Pax7, Pax3, c-Met,
M-cadherin, CD34, Syndecan-3, and calcitonin (80, 81). Recent
experiments showed that, in contrast to cultured myoblasts, satel-
lite cells freshly isolated or satellite cells derived from the transplan-
tation of one intact myofibre, contribute robustly to muscle repair.
However, because satellite cells are known to be heterogeneous,
clonal analysis is required to demonstrate stem cell function.
There is consensus that the use of testosterone leads ultimately
to regulate skeletal muscle mass by a net increase in protein syn-
thesis over degradation. In addition for changes at the skeletal
muscle level, it has been described that other cell types are involved
in testosterone-induced muscle functions. Testosterone has direct
effects on satellite cells, because they express the androgen receptor
and in response to testosterone increase the satellite cell popula-
tion. This cell proliferation is followed by a subsequent increase
in the myonuclei number of the mature skeletal muscle, through
the fusion of the satellite cells with pre-existing fibers resulting in
muscle hypertrophy (12, 54, 82). Mesenchymal stem cells (MSCs)
are a group of non-hematopoietic stem cells residing in bone mar-
row that can be used to treat a variety of degenerative diseases,
including musculoskeletal diseases. The mechanism proposed to
explain the effect of testosterone on fat-free mass, highlights the
involvement of the androgen receptor in the commitment of an
undifferentiated cell type into a myogenic cell line (83, 84).
THERAPEUTIC APPROACHES IN SARCOPENIA
Age-related frailty and sarcopenia have emerged as important
public health concerns because of their negative impact on mobil-
ity, quality of life, and health care resources (85, 86). Nutrition
and physical activity are two modifiable factors that can affect
the development of sarcopenia. Improving either or both, nutri-
tion and physical activity, may reduce the age-related low-grade
chronic inflammation and/or activate the intrinsic anabolic path-
ways in skeletal muscle. While resistance exercise, which has
assumed a prominent role in the treatment of sarcopenia, has been
shown to improve skeletal muscle mass and strength in sarcopenic
patients, it has not always been observed to improve functional
parameters (87).
Androgen treatment has been observed to enhance skeletal
muscle strength and size (30, 88, 89), but the biological mech-
anisms underlying androgen action in skeletal muscle are not
completely known. In a review of six studies of TRT in elderly
men, Borst reported that several studies found that testosterone
treatment increased lean mass and decreased fat mass whereas
one study observed increased strength (7).
ANABOLIC INTERVENTIONS
Muscle plasticity and regeneration are key processes in a num-
ber of myopathies, including muscular dystrophy, neuromuscular
disorders, and aging. Recent years have witnessed a growing inter-
est in using anabolic interventions to counteract loss of muscle
mass and function associated with age-related decreases in testos-
terone levels in men. Observation that low levels of testosterone
are associated with decreases in fat-free mass, ASM, and strength
in hypogonadal males compared to healthy controls has served as
the basis to use TRT to treat hypogonadal men (90). With age,
not only do testosterone levels decline progressively but SHBG
levels also increase, further decreasing the amount of bioavailable
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testosterone. The prevalence of hypogonadism is approximately
20% in men over 60 years and can reach 50% in men over 80 years
(31). In young hypogonadal men, TRT has been associated with
increase in lean mass, muscle strength, and muscle protein synthe-
sis and decrease in fat mass. However, in eugonadal men, changes
in body composition following TRT have not always been followed
by increase in muscle strength (91), leading to controversy regard-
ing the ergogenic effect of TRT. In one study, TRT increased bone
mass only in the group of patients with hypogonadism (89). In
addition, several studies found that administration of supraphys-
iological doses of testosterone to hypogonadal patients resulted in
outcomes similar to those obtained with resistance exercise (9).
Testosterone replacement therapy can be administered through
several routes, including intramuscularly, transdermally,and orally
(i.e., via testosterone undecanoate). Unfortunately, few studies of
the safety of TRT using any of these routes, specifically its associa-
tion with prostate cancer and cardiovascular disease in the elderly
have been conducted. Moreover, the few studies that have been
conducted were only observational or examined administration
of only very high levels of testosterone. To date, TRT has been
observed to induce and exacerbate sleep apnea, transient fluid
retention, gynecomastia, increase red cell mass, and increase the
size of both benign and malignant prostate tumors (31). TRT
for hypogonadal patients has also been hypothesized to increase
cardiovascular risk through its effect on lipid metabolism.
Many studies reporting an increase in muscle strength with TRT
suffered from methodological problems, such as lack of a control
group, lack of control for the effects of exercise, lack of control
of the dose(s) of the hormones administered to maintain normal
levels of circulating testosterone, or the inclusion of a very small
number of patients. In a meta-analysis that pooled data from 19
randomized placebo-controlled trials, Calof et al. (28) reported
that compared to placebo-treated men, testosterone-treated men
were found 1.8 times more likely to experience prostate events,
including prostate cancer, elevated prostate-specific antigen level,
and prostate biopsy, but not at a level that differed significantly at
the individual level. They also found that testosterone-treated men
were, 3.67 times more likely to experience hematocrit over 50%,
the most common testosterone-related adverse event, but did not
experience cardiovascular events at a significantly higher rate (28).
In a randomized placebo-controlled trial of 44 men with late-
onset hypogonadism aged 44–78 years, Marks et al. (92) found that
6 months of TRT normalized serum testosterone levels while only
slightly and insignificantly increasing androgen levels in prostate
tissue and volume, prostate-specific antigen, voiding symptoms,
and affecting urinary flow, and did not alter prostate tissue compo-
sition, biomarkers of cell proliferation, gene expression, or cancer
incidence or severity (92, 93).
Observation that levels of dehydroepiandrosterone (DHEA), a
precursor of various sex steroids produced in the adrenal cortex,
decline gradually with age from the third decade of life has moti-
vated research examining whether DHEA supplementation can
reverse the pathophysiological changes associated with aging. It
is hypothesized that DHEA supplementation can increase muscle
strength by increasing ratio of circulating testosterone to cortisol.
In a study of men and women aged 50–65 years, (90) observed that
supplementation with 100 mg of DHEA for 6 months increased
lean body mass and decreased fat mass in both sexes, but increased
muscle strength only moderately and only in men, and increased
testosterone levels only in women. In a randomized placebo-
controlled trial of 50 mg/day of DHEA supplementation for 1 year
to men and women aged 60–80 years, (94) failed to reproduce
Morales’s results or detect an increase in lean mass, as indicated by
measurements of body potassium.
Oxandrolone, an androgenic steroid with powerful anabolic
effects that can be administered orally, is resistant to hepatic
metabolism and thus less hepatotoxic compared to other oral
androgens. Moreover, its side effects, which include discrete eleva-
tions in transaminase levels and decreased high-density lipopro-
tein cholesterol levels, are mild and transient (95). Despite these
advantages, no clinical studies of oxandrolone administration to
elderly patients with sarcopenia have been conducted to date.
However, previous studies of skeletal muscle wasting in cachexia
associated with HIV infection, chronic neuromuscular condi-
tions, and disease-related loss of muscle mass have indicated that
oxandrolone increases protein synthesis in skeletal muscle, and is
thus associated with increased physical activity capacity and level,
increased energy and protein intake, reduced visceral and total
fat mass, and improvement in nitrogen retention (96). Therefore,
oxandrolone administration may be a therapeutic strategy in the
treatment of sarcopenia in the elderly.
Supplementation with selective androgen-receptor modulators
(SARMs) has emerged as a means of treating muscle and bone
disorders, mainly because of the specificity of SARM action and
the relatively few side effects of SARM treatment. Research using
experimental models has demonstrated that administration of
SARM S-4 exerts potent anabolic effects on skeletal muscle and
bone and only minimal effects on the prostate (97). In a recent ran-
domized, double-blind, placebo-controlled study of 170 women
aged ≥65 with sarcopenia and moderate physical dysfunction
found that 6 months of treatment with MK-0773 significantly
improved physical performance measures (98). GTx-024 (eno-
bosarm), a non-steroidal SARM that exerts tissue-selective ana-
bolic effects in muscle and bone while sparing other androgenic
tissue related to hair growth in women and prostate effects in
men, has demonstrated promising pharmacologic effects in pre-
clinical studies and favorable safety and pharmacokinetic profiles
in phase I investigations. Thus GTx-024 supplementation resulted
in dose-dependent improvement in total lean body mass and phys-
ical function and was well tolerated (99). Treatment with one or
more of the numerous other SARMs currently under study may
emerge as therapeutic alternatives to androgen agonist therapy.
The intense research into pharmacological modulation of andro-
gens and androgen intracellular signaling pathways may lead to the
development of effective approaches to restoring and preventing
the muscle loss observed in sarcopenia.
TREATMENT ALTERNATIVES AND CONCERNS
Because sarcopenia is a multifactorial disease, this should be
treated using a variety of therapeutic approaches including diet,
exercise, and pharmacology. Among current therapies, resistance
exercise and androgen replacement therapy appear to be effec-
tive alternatives for sarcopenia because both modulate multiple
tissues including musculoskeletal function. Therefore, in older
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men with sarcopenia a program of physical exercise together
with TRT emerges as a promising therapeutic alternative. A great
concern over the previous decade was that androgen supplemen-
tation increased risk of cardiovascular and prostate events. How-
ever, recent research has shown no association between androgen
supplementation and increased cardiovascular risk (with several
studies even identifying an association between low levels of testos-
terone and cardiovascular risk) nor between androgen supplemen-
tation and prostate disease. The development of “state-of-the-art”
testosterone treatments has called for wide-scale longitudinal pop-
ulation studies to determine their profile. While other anabolic,
such as DHEA, oxandrolone, and SARMs appear to be promis-
ing agents in sarcopenia treatment, further research is required
before recommendations regarding their pharmacological use can
be developed.
A decline in homeostatic and regenerative capacity occurs in
aging, where a degenerative change in stem cells homeostasis has
been postulated. Cell replacement therapy is a potential alterna-
tive treatment currently undergoing clinical trials (100). However,
in elderly human muscle they are in extremely limited supply,
hence there is a high demand for an alternative satellite cell source.
There are a number of potential sources of muscle stem cells for
cell replacement therapies such as bone marrow-derived stem cells,
hematopoietic stem cells, and MSCs. However, there are significant
controversies regarding both the efficiency and the reality of skele-
tal muscle differentiation by many of these stem cell types. Among
these cell sources, satellite cells unquestionably undergo the most
efficient musculogenesis. The actual focus in stem cell therapy,
implicate to enhance satellite cell activity by environmental con-
ditions and stem cell transplant into damaged tissues. Recently,
it has been described that satellite cells can be transplanted into
the muscle of mice, and they are able to proliferate. Moreover,
these stem cells generate a massive proliferation during muscle
injury (100). A recent in vitro study showed that treatment of
10T1/2 pluripotent mesenchymal cells with testosterone or DHT
significantly increased the number of myogenic cells in a dose-
dependent manner, while inhibiting adipogenic differentiation
(101, 102). This study demonstrated that these effects are mediated
through an AR-dependent mechanism, because an AR antagonist
blocked the actions of testosterone or DHT. This hypothesis is
also supported by the fact that in humans, CD34+ interstitial,
mesenchymal cells are AR positive and expression of the AR is
androgen dose-dependent (13, 102).
These data demonstrate that androgens can recruit stem cells
into the myogenic lineage by committing them to myogenic pre-
cursor cells (101, 103). However, it is still not known whether
androgen stimulation of myogenic commitment then gives rise to
satellite cells, or directly contributes to muscle formation. More-
over, the physiological significance of the effects of androgens
on stem cell commitment in contributing to muscle growth and
regeneration is unclear. These preliminary studies clearly indi-
cate that further investigation into this area is promissory and
necessary.
CONCLUSION
As an emerging syndrome with an increasing prevalence, sarcope-
nia has the potential to affect all aging adults. Therefore, we must
consider that in older men with low testosterone levels and symp-
toms of androgen deficiency, hormone replacement therapy in
combination with physical activity and proper nutrition will result
in increased muscle mass and strength. However, data on the clini-
cal effects of androgen replacement therapy to physiological ranges
are not yet available. With the increasing aging of most of the
world’s populations, research into this disabling disease, which
not only decreases quality of life but also increases risk of mortal-
ity, is urgently required. Identification of the pathophysiological
mechanisms underlying sarcopenia and the development of ther-
apeutic approaches will improve the quality of life not only of the
current elderly population, but all of us when we walked into our
“golden years”.
HIGHLIGHTS
• Sarcopenia is a decrease in skeletal muscle mass and function
associated with age.
• Local and systemic factors as testosterone levels are associated
with sarcopenia.
• No one of the several treatments for sarcopenia has been found
clearly superior.
• Exercise, proper nutrition, and testosterone supplementation
may treat sarcopenia.
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